The MarketReader Minute
💊 Biotech ETF dips despite Year-to-date gains; Regeneron, BioNTech weigh on IBB | Biotech Sector Insights
IBB fell 0.7% since Friday on heavy trading volume, even as it remains up 8.25% YTD and posted a 3.55% weekly gain. Regeneron slipped despite positive Phase 3 antibody trial data, while Moderna and BioNTech declined on lung cancer trial updates.